Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051

Sarepta Therapeutics has, last week, announced thatthey will be hosting a webcast and conference call to present resultsfrom the 30 mg/kg arm of the MOMENTUM study. This study is a multiple-ascendingdose clinical trial of SRP-5051 for Duchenne muscular dystrophy.

 The presentation will be webcast live under the investorrelations section of Sarepta's website on Monday, May 3, 2021 at 8:30 amEastern Time.   

To read the full press release, click the link below:

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

Back to News